Moderna, a biotech company made famous by providing one of the first COVID-19 vaccines, has started human trials of a vaccine against HIV.

The nonprofit scientific research organisation announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C.

In a release they say that:

The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology

That is still a long way from it being a proven vaccine let alone a publicly available drug, but offers a fresh round of hope to many. After generations of our LGBT+ communities – and others – being devastated by the effect of HIV/AIDS, and related stigma, we wish the participants and researchers the best possible outcome for the trial… but we’ll wait to see before celebrating too much.

Moderna tweeted today: “ANNOUNCEMENT : We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1644, our experimental #HIV #mRNA #vaccine candidate.”